WHITEHOUSE STATION, N.J. and SHENZHEN, China, Sept. 13, 2011 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and BGI established a collaboration to focus on the discovery and development of biomarkers and genomic technologies. Under the agreement scientists from Merck and BGI will work closely together to identify and characterize biomarkers with an emphasis on drug discovery, drug development and diagnostics applications across a wide range of therapeutic areas. 

NEW YORK, N.Y., CAMBRIDGE, M.A. and SHENZHEN, CHINA (October 13, 2011) – Autism Speaks, the world’s largest autism science and advocacy organization, and BGI entered into a partnership to create the world’s largest library of sequenced genomes of individuals with autism spectrum disorders (ASD). Using the Autism Speaks Autism Genetic Resource Exchange (AGRE), this collaboration will perform whole genome sequencing on more than 2,000 participating families who have two or more children on the autism spectrum. The data from the 10,000 AGRE participants will enable new research in the genomics of ASD, and significantly enhance the science and technology networks of both Autism Speaks and BGI. In addition, Autism Speaks and BGI will collect and sequence genome samples from individuals in China.

Seattle, WA and Shenzhen, China September 25, 2012 – BGI and the Bill & Melinda Gates Foundation have signed a Memorandum of Understanding (MOU) to form a collaboration on global health and agricultural development with the goal of achieving common objectives in health and agricultural development, and meaningfully contributing to the achievement of one or more of the Millennium Development Goals. The signing ceremony, attended by Dr. Jian Wang, Director and Co-founder of BGI, Dr. Jun Wang, Executive Director, BGI, and Bill Gates of the Gates Foundation, was conducted yesterday outside of Seattle, Washington.

Cambridge, MA and Shenzhen, China, March 21, 2013 — H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, and BGIentered into a partnership to sequence and publish genomic data from pre-clinical cancer models. This research, which aims to identify and validate recurrent gene mutations that are potential targets for drug therapies, is crucial for the entire oncology drug discovery industry. Consistent with their respective ongoing commitments to open-access research, as well as BGI’s distinguished history of published, collaborative research, H3 and BGI will release the cancer genomic data to the global research community upon completion of data analysis.